Home
/
Arcus Biosciences, Inc.
/
Financials
/
Quarterly
Arcus Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Arcus Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$26.00M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$160.00M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$28.00M
May 6, 2025
Q3
2025
Sep 30, 2024
$48.00M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$39.00M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$145.00M
May 6, 2025
Q3
2019
Sep 30, 2019
$1.75M
Nov 5, 2019
Q2
2019
Jun 30, 2019
$1.75M
Aug 6, 2019
Q1
2019
Mar 31, 2019
$1.75M
May 2, 2019
Q3
2019
Sep 30, 2018
$4.29M
Nov 5, 2019
Q2
2019
Jun 30, 2018
$1.25M
Aug 6, 2019
Q1
2019
Mar 31, 2018
$1.25M
May 2, 2019
Q3
2018
Sep 30, 2017
$163.0K
Nov 8, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$6.00M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$8.00M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$8.00M
May 6, 2025
Q3
2025
Sep 30, 2024
$7.00M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$11.00M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$10.00M
May 6, 2025
Q3
2024
Sep 30, 2023
$32.00M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$29.00M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$25.00M
May 8, 2024
Q3
2023
Sep 30, 2022
$33.00M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$27.00M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$18.00M
May 9, 2023
Q3
2022
Sep 30, 2021
$9.46M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$9.46M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$9.46M
May 9, 2022
Q3
2021
Sep 30, 2020
$64.53M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$1.75M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.75M
May 5, 2021
Q3
2020
Sep 30, 2019
$1.75M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$1.75M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($135.00M)
Oct 28, 2025
Q2
2025
Jun 30, 2025
$0
Aug 6, 2025
Q3
2025
Jun 30, 2025
$0
Oct 28, 2025
Q2
2025
Mar 31, 2025
($112.00M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($112.00M)
Oct 28, 2025
Q1
2025
Mar 31, 2025
($112.00M)
May 6, 2025
Q3
2025
Sep 30, 2024
($92.00M)
Oct 28, 2025
Q3
2025
Jun 30, 2024
($93.00M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($93.00M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($4.00M)
Oct 28, 2025
Q2
2025
Mar 31, 2024
($4.00M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($4.00M)
May 6, 2025
Q3
2024
Sep 30, 2023
($71.00M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($75.00M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($75.00M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
($80.00M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($80.00M)
May 8, 2024
Q3
2024
Mar 31, 2023
($80.00M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($65.00M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($67.00M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($142.00M)
Oct 28, 2025
Q2
2025
Jun 30, 2025
($8.00M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($122.00M)
May 6, 2025
Q3
2025
Sep 30, 2024
($105.00M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($106.00M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($16.00M)
May 6, 2025
Q3
2024
Sep 30, 2023
($80.00M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($83.00M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($86.00M)
May 8, 2024
Q3
2023
Sep 30, 2022
($70.00M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($69.00M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($67.00M)
May 9, 2023
Q3
2022
Sep 30, 2021
($78.14M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($76.14M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($72.75M)
May 9, 2022
Q3
2021
Sep 30, 2020
$1.55M
Nov 8, 2021
Q2
2021
Jun 30, 2020
($45.38M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($28.40M)
May 5, 2021
Q3
2020
Sep 30, 2019
($23.25M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($29.16M)
Aug 6, 2020